Fig. 4From: A phase II clinical trial to investigate the effect of pioglitazone on 18F-FDG uptake in malignant lesions a, b, c, d, e, f Changing patterns of PET parameters in the non-responder group. The PET parameters show decreasing patterns in both malignant and inflammatory lesions after the use of PIO. There are no significant differencesBack to article page